Top HCV stories of 2014

Hepatitis C virus infection entered a new era this year, following FDA approvals of multiple treatment regimens, and new, groundbreaking clinical data produced by the top researchers in the field. Using web analytics, social media and expert opinion, has compiled a list of some of the most important, relevant research and news on hepatitis C virus infection presented during the past year.

FDA approves Harvoni for HCV treatment
Using the breakthrough therapy designation, the FDA approved the first combination pill for treatment of chronic hepatitis C virus genotype 1 that does not require interferon or ribavirin for administration.

Treatment-naive participants showed a 94% sustained virologic response rate after 8 weeks of treatment and a 96% SVR rate after 12 weeks. Treatment-naive patients with and without cirrhosis showed a 99% SVR rate after 12 weeks. Among treatment-experienced participants with and without cirrhosis, ribavirin did not improve response rates in any of the trials.  

Read more